2182 IMPACT OF THULIUM VAPOENUCLEATION OF THE PROSTATE (THUVEP) ON SEXUAL FUNCTION: A PROSPECTIVE SINGLE CENTER STUDY

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy and New Technology (III)1 Apr 20132182 IMPACT OF THULIUM VAPOENUCLEATION OF THE PROSTATE (THUVEP) ON SEXUAL FUNCTION: A PROSPECTIVE SINGLE CENTER STUDY Christian Tiburtius, Sophie Knipper, Thorsten Bach, and Christopher Netsch Christian TiburtiusChristian Tiburtius Hamburg, Germany More articles by this author , Sophie KnipperSophie Knipper Hamburg, Germany More articles by this author , Thorsten BachThorsten Bach Hamburg, Germany More articles by this author , and Christopher NetschChristopher Netsch Hamburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2091AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To evaluate changes in sexual function after ThuVEP for the treatment of benign prostatic obstruction (BPO) in men at 12-month follow-up. METHODS A prospective analysis of seventy-two patients who underwent ThuVEP between January and July 2011. Preoperative evaluation included transrectal ultrasound gland volume measurement, maximum urinary flow rate (Qmax), international prostate symptom score (IPSS), quality of life (QoL), post-voiding residual urine (PVR), and the International Index of Erectile Function (IIEF-5). Patients were subdivided into two groups: group A: IIEF-5 > 19 and group B: IIEF-5 < 19. Intra-, peri-, and postoperative parameters were evaluated. All patients were reassessed at 12-month follow-up by Qmax, IPSS, QoL, PVR, and IIEF-5. Patient data were expressed as median (interquartile range). RESULTS Median patient age was 70 (65-73) years and the median prostate volume was 52.5 (39.75-72) ml, respectively. At 12-month follow-up, IPSS (20 vs. 4), QoL (4 vs. 1), Qmax (9.7 vs. 22.15 ml/s), and PVR (100 vs. 15 ml) improved significantly in comparison to preoperative assessment (p < 0.001) with no statistical differences between group A and B. A slight but no significant increase in the IIEF-EF domain score was reported at 12-month follow-up (19.5 vs. 20), which could also be shown in group A (25 vs. 26) and group B (6 vs. 8), respectively. CONCLUSIONS ThuVEP is an efficacious procedure for the treatment of BPO. ThuVEP did not impact erectile function in patients with normal preoperative erectile function (IIEF-EF > 19) and those with preoperative existing erectile dysfunction (IIEF-EF < 19). © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e894-e895 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christian Tiburtius Hamburg, Germany More articles by this author Sophie Knipper Hamburg, Germany More articles by this author Thorsten Bach Hamburg, Germany More articles by this author Christopher Netsch Hamburg, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...